GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (STU:26CA) » Definitions » Additional Paid-In Capital

ImmunityBio (STU:26CA) Additional Paid-In Capital : €2,211.42 Mil(As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is ImmunityBio Additional Paid-In Capital?


ImmunityBio's quarterly additional paid-in capital increased from Sep. 2023 (€2,169.83 Mil) to Dec. 2023 (€2,177.53 Mil) and increased from Dec. 2023 (€2,177.53 Mil) to Mar. 2024 (€2,211.42 Mil).

ImmunityBio's annual additional paid-in capital increased from Dec. 2021 (€1,521.94 Mil) to Dec. 2022 (€1,822.80 Mil) and increased from Dec. 2022 (€1,822.80 Mil) to Dec. 2023 (€2,177.53 Mil).


ImmunityBio Additional Paid-In Capital Historical Data

The historical data trend for ImmunityBio's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunityBio Additional Paid-In Capital Chart

ImmunityBio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
- 1,229.02 1,521.94 1,822.80 2,177.53

ImmunityBio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,836.09 1,837.32 2,169.83 2,177.53 2,211.42

ImmunityBio Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

ImmunityBio Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of ImmunityBio's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmunityBio (STU:26CA) Business Description

Traded in Other Exchanges
Address
3530 John Hopkins Court, San Diego, CA, USA, 92121
ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. Geographically, the company operates in United States and Europe. Majority of the revenue is generated from Europe.

ImmunityBio (STU:26CA) Headlines

No Headlines